Method for normalising spontaneous erythrocyte aggregation in newborn piglets with iron-deficiency anaemia

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method involves in the fact that intramuscular injections of ferroglucinum 150 mg twice every four days are combined with crezacin 4 mg/kg a day of fed-on plan in the morning for 5 days and intramuscular injections of gamavit 0.03 ml/kg once a day in the morning for 5 days.

EFFECT: method enables normalising spontaneous erythrocyte aggregation in piglets, sanitising seed stock, reducing death loss, providing higher weight gain and high-quality meat products.

3 ex

 

The invention relates to biology and veterinary medicine.

The closest analogue to the proposed method of normalization of the spontaneous aggregation of erythrocytes (SAE) in newborn piglets with anemia is the way EN 2403029, which along with threefold introduction feroglobin are complex regimen of injections fosrenol and amavita that allows to normalize SAE only after 18 days of treatment. The need for long-term use of the prototype for complex regimen dosing metabolically important components complicates its practical use in comparison with more simple in application of the claimed method, which allows to normalize SAE newborn piglets with iron deficiency anemia after 5 days after 5-day treatment.

The aim of the invention is the normalization of SAE in newborn piglets with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the normalization SAE newborn piglets with iron-deficiency anemia is assigned to feroglobin 150 (2 ml) intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day, included in the scheme, drink in the morning for five days, starting simultaneously with the first injection feroglobin and gamavit 0.03 mg/kg intramuscularly once a day, in the morning, within five days, starting simultaneously with ferragu is different and krezacin.

The method enables stable to normalize SAE newborn piglets with iron deficiency anemia after 5 days after treatment. In the subsequent data piglets SAE stabilized at a normal level, which can significantly improve the livestock of pigs, to normalize the gain, reduce their pathological burden, reduce mortality and improve the quality received from meat products.

The inventive method is carried out as follows.

Erythrocyte aggregation is assessed by the degree of ability of erythrocytes to spontaneously aggregate (Pokrova O.A., Grineva MR, Ivanov K.S. Methodology and clinical significance of the study the rheological properties of blood // Bulletin of the Ivanovo medical Academy. - 2008. - T13, No. 1-2, - s.89-98).

To assess the aggregation of erythrocytes blood from a vein taken in sodium citrate in the ratio of 9:1 and centrifuged 10 min at 3000 rpm./minutes In 96-well pad fill 2 holes 0.2 ml plasma of the subject. From the tube removed all the plasma and the layer of leukocytes. Erythrocytes resuspended standard phosphate buffer in the ratio 1:4, followed by centrifugation for 10 min at 3000 rpm./min, allowing you to wash them from the remnants of the plasma when removing the supernatant. After this is taken as 0.02 ml of erythrocytes and resuspended first filled AutoLog is offered by the plasma-well 96-well planchettes, that allows you to receive 10% hematocrit. Then from this hole, take a clean, dry pipette 0,02 ml content and placed in the second filled the hole that allows you to get 1% hematocrit. After that 1 grid in the camera Goryaeva fill obtained a suspension of red blood cells, incubated 3 min for the occurrence of spontaneous aggregation and shall count free erythrocytes (including 2 of the erythrocyte together) and units, starting with 3 cells, connected in the form of "monetary columns") in 2 large squares of the camera (lens x 40 x 10 eyepiece). Considered the number of "coin of columns and the number of red blood cells, involved in them.

Based on these results, calculate the following indicators that assess SAE:

1) Average unit size (CPA):

CPA=sea/KA,

where VOC is the sum of all cells in the units;

KA - the number of units.

2) the Index of aggregation (PA):

PA=(PA·KA+CTU)/(KA+CTU),

where CTU - free erythrocytes.

3) the Percentage of non-aggregated RBCs (PNA):

PNA=CSE·100/(PA·KA+CTU)

Normative values for CPA are 4-5, PA 1,05-1,30, for the PNA 80,0-92,0%. The increase in CPA more than 5 PA above 1.30 and lowering the PNA below 80,0% talks about increasing the SAE. In case of violation of at least one of these three indicators of sick animals must be treated according to the claimed method, including the nes, feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day in the schema drink for 5 days at a time with the first injection feroglobin and gamavit of 0.03 ml/kg intramuscularly once a day for five days, starting simultaneously with ferroaluminum and krezacin.

The use of the claimed complex normalizes SAE newborn piglets with iron deficiency anemia after 5 days after treatment. This is the basis of recovery of the herd, reducing mortality and guarantee of high quality meat products from treated with it, pigs.

Example 1. The newborn Piglet No. 26 with iron deficiency anemia were identified impaired erythropoiesis with signs of decreased levels of iron in the body (serum iron of 13.1 µmol/l, siderocyte 1.4%, hemoglobin of 79.6 g/l, erythrocytes is 3.82×1012l).

In the morning the animal was taken a blood from a vein and is defined SAE caught high (CPA=5,7, PA=1.81, the PNA=56,9%). The pig was assigned feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day in the schema drink in the morning for 5 days and gamavit of 0.03 ml/kg intramuscularly once daily in the morning for five days. The use of all components of the medical complex was begun at the same time.

Through 5 days after the treatment, a pig, a registered floor is th normalization of serum iron (22,0 µmol/l), siderocyte (8,2%), the amount of hemoglobin (126,5 g/l) and erythrocyte (5,41×1012/l) with a stable normalization SAE (CPA=4,3, PA=1,16, PNA=by 83.4%). In the subsequent performance of the pig did not experience negative dynamics.

Example 2. The newborn Piglet No. 29 with iron deficiency anemia were identified impaired erythropoiesis with signs of decreased levels of iron in the body (serum iron to 12.0 mmol/l, siderocyte of 1.1%, the amount of hemoglobin of 82.6 g/l, the level of erythrocytes 3,74×1012l).

In the morning the pig was taken a blood from a vein and is defined SAE caught high (CPA=5,8, PA=1,77, PNA=57,4%). The pig was assigned feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day in the schema drink in the morning for 5 days and gamavit of 0.03 ml/kg intramuscularly once daily in the morning for five days. The use of all components of the medical complex was begun at the same time.

Through 5 days after the end of treatment the pig reached full normalization of serum iron (26,1 µmol/l), siderolites (8,9%), the amount of hemoglobin (129,1 g/l) and erythrocyte (5,32×1012l) and SAE (CPA=4,7, PA=1,19, PNA=86,3%). Subsequent observation carried indices in this pig did not experience negative dynamics.

Example 3. The newborn Poros the NCA No. 32 with iron deficiency anemia were identified impaired erythropoiesis with signs of decreased levels of iron in the body (serum iron 11.5 µmol/l, siderocyte 1.4%, hemoglobin of 78.6 g/l, erythrocytes 3,74×1012l).

In the morning the animal was taken a blood from a vein and is defined SAE caught high (CPA=5,8, PA=1,85, PNA=61,4%). The pig was assigned feroglobin 150 mg (2 ml) intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day in the schema drink in the morning for 5 days and gamavit of 0.03 ml/kg intramuscularly once daily in the morning for five days. The use of all components of the medical complex was begun at the same time.

Through 5 days after the end of treatment the pig reached full normalization of serum iron (25,8 µmol/l), siderolites (8,2%), the amount of hemoglobin (to 127.9 g/l) and erythrocyte (5,5×1012/l) and SAE (CPA=4,2, PA=1,23, PNA=89,0%). In subsequent normalizovalsya indicators of Piglet felt no negative dynamics.

The use of the claimed method has been successfully tested at 225 newborn piglets with iron deficiency anemia with achievement of full normalization SAE in all cases.

The method of normalization of the spontaneous aggregation of erythrocytes of newborn piglets with iron deficiency anemia, characterized in that simultaneously applies feroglobin 150 mg intramuscularly, dmocrate with an interval of 4 days, krezacin 4 mg/kg per day in the schema drink in the morning for five days and gamavit of 0.03 ml/kg intramuscularly once daily in the morning, within five days.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method involves the use of intramuscular injections of ferroglucinum 75 mg at 15 mg of iron per 1 kg of calf's body weight, once in a combination with feeding of glycopine 6.0 mg/day in the morning for 6 days starting simultaneously with injections of ferroglucinum 75.

EFFECT: method is high-effective in correction of blood antithrombin III activity.

1 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula possessing action on a BH4 sensitive condition.

EFFECT: invention refers to a pharmaceutical composition containing said compound to applying the compound for preparing a drug for treating the BH4 sensitive condition, such as a vascular disease, a psychoneurological disease, hyperphenylalaninemia.

12 cl, 31 dwg, 20 ex

FIELD: veterinary medicine.

SUBSTANCE: calves are injected intramuscularly as a single dose the solution of ferroglucine-75 on the basis of 15 mg of iron per 1 kg of live weight of a calf, and glicopin is fed 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection of ferroglucine-75.

EFFECT: method enables to normalise the antioxidant activity of the liquid part of the blood of newborn calves with iron deficiency anemia, to increase the reactivity of the animal organism, to reduce the risk of thrombotic complications, promotes normal growth and development of calves.

2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to dihydropyrazolone derivatives or of formula (I), where R1 denotes a heteroaryl group of formulae given below, where * denotes the linkage point with the dihydropyrazolone ring, A in each individual occurrence denotes C-R4 or N, wherein at most two ring members A represent N at the same time, E denotes O or S, R2, R3 and R4 are as defined in the claim. The invention also relates to a method of producing said compounds.

EFFECT: compounds of formula (I) inhibit HIF-propylhydroxylase activity and can be used to treat and/or prevent diseases, as well as for producing medicaments for treating and/or preventing diseases, particularly cardiovascular and haematologic diseases, kidney diseases, and for promoting the healing of wounds.

10 cl, 10 tbl, 178 ex

FIELD: medicine.

SUBSTANCE: what is offered is using cyproheptadine as an agent preventing developing disorders in pulmonary tissue and blood system caused by the introduction of cytostatics. It is shown that cyproheptadine prevents alveoli infiltration, oedema of interalveoral septum, connective tissue development in lungs with reducing blood lymphocyte count and peripheral blood and bone marrow neutrophilic granulocyte count.

EFFECT: invention may be used for pharmacological correction of pulmonary fibrosis and blood system disorders developing with prescribing anticancer preparations.

1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine and concerns the use of dihydrobromide 9-(2-diethylaminoethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole of formula as a biologically active compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and a based pharmaceutical composition.

EFFECT: preparing the compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and the based pharmaceutical composition.

2 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 solution in dose 15 mg of iron per 1 kg of live weight of calf body, one time, intramuscularly and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: method makes it possible to stably normalise thrombotic hemostasis in newborn calves with iron-deficient anemia, ensures long-time support of thrombotic hemostasis in optimal mode of functioning, excludes risk of thrombotic complications and assists normal growth and development of calves.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes the pyrrolo- and thiazolopyridinium compounds and their pharmaceutically acceptable salts covered by general structural formula I: wherein the values A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are those as presented in cl.1, and a pharmaceutical composition based on the given compound for inhibition of hypoxia-inducible factor (HIF) hydroxylase activity.

EFFECT: there are produced and described new compounds able to modulate hypoxia-inducible factor (HIF) stability and/or activity.

29 cl, 178 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel cyanoisoquinoline derivatives of formula I , where R is selected from a group comprising hydrogen and C1-C10 alkyl, R1, R2, R3 and R4 are independently selected from a group comprising hydrogen, halogen, hydroxy, C1-C10 alkyl, substituted with 1-3 halogen atoms or C6-C14 acryl, C6-C14 aryl, -OR7, -SR7 and -SO2R7, where R7 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14 aryl, C3-C10 cycloalkyl, C6-C14 aryl and C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino and C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R5 and R6 are independently selected from a group comprising hydrogen and C1-C3 alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II , where R31, R32, R33 and R34 are independently selected from a group comprising hydrogen, hydroxy, halogen, C1-C10 alkyl substituted with 1-3 halogen atoms or with C6-C14 aryl, C6-C14 aryl, -OR37, -SR37 and -SO2R37, where R37 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14aryl, C3-C10 aryl, C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, R35 denotes hydrogen or methyl, or pharmaceutically acceptable salts thereof. The invention also relates to specific cyanoisoquinoline compounds, a pharmaceutical composition based on the compound of formula I, a hypoxia-inducible factor (HIF) hydroxylase inhibiting method, a method of treating, preventing or slowing down development of a condition associated with hypoxia-inducible factor (HIF), a condition associated with erythropoietin (EPO), anaemia, based on use of the compound of formula I.

EFFECT: obtaining novel cyanoisoquinoline compounds having useful biological properties.

42 cl, 1 tbl, 54 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method involves the use of intramuscular injections of ferroglucinum 75 mg at 15 mg of iron per 1 kg of calf's body weight, once in a combination with feeding of glycopine 6.0 mg/day in the morning for 6 days starting simultaneously with injections of ferroglucinum 75.

EFFECT: method is high-effective in correction of blood antithrombin III activity.

1 dwg, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: calves are injected intramuscularly as a single dose the solution of ferroglucine-75 on the basis of 15 mg of iron per 1 kg of live weight of a calf, and glicopin is fed 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection of ferroglucine-75.

EFFECT: method enables to normalise the antioxidant activity of the liquid part of the blood of newborn calves with iron deficiency anemia, to increase the reactivity of the animal organism, to reduce the risk of thrombotic complications, promotes normal growth and development of calves.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 solution in dose 15 mg of iron per 1 kg of live weight of calf body, one time, intramuscularly and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: method makes it possible to stably normalise thrombotic hemostasis in newborn calves with iron-deficient anemia, ensures long-time support of thrombotic hemostasis in optimal mode of functioning, excludes risk of thrombotic complications and assists normal growth and development of calves.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear cation nitrosyl iron complexes with natural aliphatic thiolyls with general formula [Fe2(SR)2(NO)4]SO4 where R is aliphatic ligands of natural origin.

Also there is proposed method for production of binuclear cation nitrosyl iron complex, nitrogen monoxide donor, inductor of tumor cells apoptosis, application binuclear cation nitrosyl iron complex, pharmaceutical composition and set used for treatment of oncology diseased. The technical result is EFFECT: production of binuclear cation nitrosyl iron complex possessing cytotoxic, apoptotic and NO-donor activity.

15 cl, 2 ex, 4 tbl, 7 dwg

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear nitrosyl iron complexes with benzazeheterocyclic derivatives with general formula [Fe2(SR)2(NO)4] where R is And where X is NH, S, R1 is lower alkyl. Also there is proposed method for its production, nitrogen monoxide donor, application as oncology drug and for production of oncology drug, pharmaceutical composition and set used for treatment of oncology diseased.

EFFECT: production of binuclear nitrosyl iron complex that is used as an oncology drug with increased effectiveness and decreased toxicity.

15 cl, 3 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, applied in case of myocardial infarction and operations on heart in conditions of artificial blood circulation. Water-soluble composition for intravenous introduction, contains ingredients with the following component ratio in wt %: D-glucose 23.40-28.60; potassium chloride 0.14-0.16; potassium salt of L-asparaginic acid 0.81-0.99; semi-magnesium salt of L-asparagenic acid (magnesium L-aspartate) 0.72-0.88; human insulin genetically engineered (in IU/l) 54.00-66.00; dinitrosyl complex of iron (II) with glutathione 0.19-0.23; water for injections - remaining part, with solution pH 7.4±0.1 at 22°C.

EFFECT: application of composition ensures limitation of myocardial infraction size, recovery of metabolic condition of heart at reperfusion, reduces injury of membranes of post-ischemic cardiomyocytes with smaller haemodinamics disorders as compared with traditionally applied medications.

2 dwg, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of a tetranitrosyl complex of iron with thiophenol of formula [Fe2(SC6H5)2(NO)4] as an anti-tumour medicinal agent in order to prepare a medicinal agent for treating oncological diseases. The invention also relates to a pharmaceutical composition and a set containing said complex.

EFFECT: invention ensures high efficiency of treatment.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to complex compound of iron with carbohydrate. Complex compound, in addition to iron (III) contains iron (II). Per cent of iron (II) in terms of total amount of iron in complex compound constitutes, at least, 2 wt %. Carbohydrate is selected from group, consisting of natural carbohydrates or synthetic derivatives of carbohydrates, such as starch, hydrolysed starches, dextrins, in particular such as maltodextrin, maltose syrup, glucose syrup, cyclodextins, dextrans, saccharides. Per cent of carbohydrate in terms of complex compound of iron with carbohydrate constitutes from 10 to 80 wt %. Method of obtaining complex compound of iron with carbohydrate includes the following stages. Water solution of suspension of carbohydrate is prepared. After that, iron (III) salts are added at constant pH value within the range from 7 to 13. Iron (III) salt is selected from group, consisting of iron (III) chloride and iron (III) sulfate. Water solution or suspension is heated with further cooling. Formed complex compound of iron with carbohydrate if isolated. Precipitation of complex compound of iron with carbohydrate is performed by addition of one or more alcohols, such as ethanol or propanol. Obtained complex compound is used for production of medication for treatment of iron-deficient anemias, which is well absorbed in organism in case of peroral intake.

EFFECT: iron, included into composition of medication is better resorbed and better tolerated by organism than pure iron preparations.

26 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. A method involves the use of intramuscular injections of ferroglucinum 75 mg at 15 mg of iron per 1 kg of calf's body weight, once in a combination with feeding of glycopine 6.0 mg/day in the morning for 6 days starting simultaneously with injections of ferroglucinum 75.

EFFECT: method is high-effective in correction of blood antithrombin III activity.

1 dwg, 3 ex

Up!